Velide (propofol tenofovir fumarate tablets) (TAF) was developed by the original research company Gilead, and was approved for marketing by the FDA in November 2016, the trade name is Vermlidy, and in November 2018, the drug was approved for marketing by the State Food and Drug Administration, and the trade name was Velide.
Verider (propofol tenofovir fumarate tablets)
With the expiration of the pronofovir fumarate patent on July 21, 2021, this also means that the monopoly position of the original drug will be broken, and a large number of domestic generic drugs will be listed. Among them, propofol tenofovir fumarate produced by Qilu Pharmaceutical (Trifovi) was launched on July 28, "World Hepatitis Day".
Propofol fumarate tenofovir (trifovir) 398 yuan
Propofol fumarate tinovvir (trifovir) instructions are as follows:
Propofol fumarate tenofovir (trifolius) instruction manual
Trade name: Trilite
Generic name: Propofol tenofovir fumarate tablets
Ingredients: This product contains propofol tenofovir fumarate
Indications: Suitable for the treatment of chronic hepatitis B in adults and adolescents (age 12 years and older, weighing at least 35 kg).
Specification: 25 mg
Dosage: Adults and adolescents (ages 12 years and older and weigh at least 35 kg): One tablet once daily. Taken orally, with food.
Dosage for special populations
【Medication for pregnant and lactating women】
There are no or very limited data on the use of TAF in pregnant women, and a large number of data (more than 1000 exposure outcomes) indicate that there are no malformations or fetal/neonatal toxicity associated with tenofovir fumarate, and if necessary, the use of TAF during pregnancy may be considered
The risk to lactating children cannot be excluded, TAF should not be used during breastfeeding, and there are no relevant data on the effects of TAF on human fertility
【Pediatric medication】The safety and efficacy of TAF in children under 12 years of age or < 35 kg of body weight have not been determined. No data is available yet.
【Geriatric medication】There is no need to adjust the dose for patients aged 65 years and older.
Impaired renal function
Dose adjustment is not required for adults or adolescents≥ (aged at least 12 years and weighing at least 35 kg) or crCl < 15 mL/min with creatinine clearance (CrCl) estimates of 15 mL/min and undergoing hemodialysis.
On the day of hemodialysis, the drug should be administered after the completion of hemodialysis treatment
For patients with CrCl < 15 mL/min and not receiving hemodialysis, there is no recommended dosage for administration
Impaired liver function
Dose adjustment is not required for patients with liver impairment
There are no data on the use of propofol tenofovir in pregnant women or such data are very limited (less than 300 pregnancy outcomes). However, a large number of data on pregnant women (more than 1000 exposure outcomes) indicate that there are no morphological or fetal/neonatal toxicities associated with tenofovir fumarate.
With regard to reproductive toxicity, animal studies have not shown the presence of direct or indirect harmful effects
If necessary, the use of propofol tenofovir fumarate tablets during pregnancy may be considered.
It is unclear whether propofol tenofovir is secreted into human milk. However, animal studies have shown that tenofovir can be secreted into breast milk. Insufficient information is available about the effects of tenofovir in newborns/infants.
The risk to lactating children cannot be excluded. Therefore, propofol tenofovir fumarate tablets should not be used during lactation.
There are no data on the effect of propofol tenofovir fumarate tablets on human fertility. Animal studies have not shown that propofol tenofovir can have a detrimental effect on fertility.
【Drug Interactions】
Interaction studies have been conducted only in adults. Propofol tenofovir fumarate tablets should not be combined with drugs containing tenofovir fumarate, propylol tenofovir or adefovir ester. Drugs that may affect propofol tenofovir Propylol tenofovir is transported by P-gp and breast cancer resistant protein (BCRP). P-gp inducers are expected to reduce plasma concentrations of propofol tenofovir, which may cause propofol tenofovir fumarate tablets to lose efficacy.
【Storage】Store below 30 °C.
【Packing】30pcs/bottle, 1 bottle/box.
【Validity】24 months
【Approval number】National Pharmaceutical Approval Word H20203610
【Listing Authorization Holder】Qilu Pharmaceutical Co., Ltd. Registered address: No. 317, Xinyou Street, High-tech Zone, Jinan City, Shandong Province
【Production enterprise】Qilu Pharmaceutical Co., Ltd. Production address: No. 8888, Tourism Road, High-tech Zone, Jinan City
How much is Qilu Trihui / Telihui price / Terific Qilu price: 398
What is Trifolix: Hepatitis B First-line Medication: Velide (Propofol Tenofovir Fumarate Tablets) Generic Drugs: Trifolix (Propofol Tenofovir Fumarate Tablets)
Efficacy and function of Triphosis
As of August 2, 2021, the State Drug Administration approved the publication of Velidde (propofol tenofovir fumarate tablets) generic drugs in production by a total of 9 manufacturers, as detailed below:
1. Propofol tenofovir fumarate tablets ( Shijiazhuang Longze Pharmaceutical Co., Ltd. Sinopharm Junzi H20213310)
2. Propofol tenofovir fumarate tablets (Qilu Pharmaceutical Co., Ltd. Sinopharm Junzi H20203610)
3. Propofol tenofovir fumarate tablets (Chengdu Beta Pharmaceutical Co., Ltd. Sinopharm Junzi H20203517)
4. Propylphenol fumarate tenofovir tablets ( Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Sinopharm Junzi H20213538)
5. Propylphenol fumarate tenofovir tablets (Shanghai Diesel Biopharmaceutical Co., Ltd. Sinopharm ZH20213497)
6. Propofol fumarate tenofovir tablets ( Fujian Guangshengtang Pharmaceutical Co., Ltd. Sinopharm Quasi-word H20213289)
7. Propofol tenofovir fumarate tablets (Sichuan Kelun Pharmaceutical Co., Ltd. Sinopharm Zhongzi H20213245)
8. Propofol tenofovir fumarate tablets (Chengdu Yuandong Biopharmaceutical Co., Ltd. Sinopharm Junzi H20213274)
9. Propofol tenofovir fumarate tablets (Jiangxi Qingfeng Pharmaceutical Co., Ltd. Sinopharm Junzi H20203566)